Table 4.
Characteristics of patients in the independent test set 2
| Sample ID | Age (years) | Sex | Bacterial isolation | Antibiotherapy before blood collection | Underlying diseases | Survival |
|---|---|---|---|---|---|---|
| Other sepsis (n = 7) | ||||||
| I027* | 64 | Female | E. coli† | Fortum, ceftriaxone | UGIB | Non-survivor |
| I028‡ | 81 | Female | Corynebacterium spp. | Ceftriaxone, fortum, clindamycin | T2D | Survivor |
| I029‡ | 74 | Female | S. aureus | Fortum, ceftriaxone, tazocin | Asthma, emphysema, ARF | Survivor |
| I031* | 48 | Male | Enterococcus spp. | Fortum | Urinary tract infection | Survivor |
| I032* | 54 | Female | E. faecium | Fortum, tazocin | T2D, respiratory failure | Non-survivor |
| I033* | 63 | Female | E. coli† | Tazocin, ceftriaxone, fortum | T2D, ovarian cancer | Survivor |
| I034* | 43 | Male | A. hydrophila† | Tazocin | - | Survivor |
| Septicemic melioidosis (n = 8) | ||||||
| M031* | 49 | Male | B. pseudomallei | Fortum, bactrim, tazocin | T2D | Non-survivor |
| M032* | 54 | Male | B. pseudomallei | Fortum, doxycycline, sulperazone | T2D | Non-survivor |
| M033* | 44 | Male | B. pseudomallei | Fortum, sulperazone, bactrim, ciprofloxacin | T2D | Survivor |
| M034* | 40 | Female | B. pseudomallei | Fortum, bactrim, ceftazidime, ceftriaxone | T2D | Survivor |
| M035* | 56 | Male | B. pseudomallei | Ceftriaxone, ceftazidime, fortum | COPD, T2D | Non-survivor |
| M036* | 41 | Female | B. pseudomallei | Ceftriaxone, ceftazidime | T2D | Non-survivor |
| M037* | 42 | Female | B. pseudomallei | Bactrim, fortum, cloxacillin | T2D | Survivor |
| M038* | 49 | Female | B. pseudomallei | Ceftriaxone, fortum, ceftazidime, levofloxacin | - | Non-survivor |
*Community-acquired septicemia; ‡hospital-acquired septicemia. †Positive by two sets of blood cultures. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; T2D, type 2 diabetes; UGIB, upper gastrointestinal bleeding.